Difference between revisions of "Valrubicin (Valstar)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chro...") |
m |
||
| Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.valstarsolution.com/pdf/patient_brochure.pdf "Understanding Your Therapy With VALSTAR"] | + | *[http://www.valstarsolution.com/pdf/patient_brochure.pdf Valrubicin (Valstar) manufacturer's patient drug information - "Understanding Your Therapy With VALSTAR"] |
*[http://www.uptodate.com/contents/valrubicin-patient-drug-information Valrubicin (Valstar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/valrubicin-patient-drug-information Valrubicin (Valstar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/valrubicin-patient-drug-information Valrubicin (Valstar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/valrubicin-patient-drug-information Valrubicin (Valstar) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 01:06, 26 February 2012
General information
Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.[1][2][3]
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Valrubicin (Valstar) manufacturer's patient drug information - "Understanding Your Therapy With VALSTAR"
- Valrubicin (Valstar) patient drug information (UpToDate)[4]